Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are coping, thank you, despite the raging tumult underway beyond the walls of the Pharmalot campus. For those needing a moment of relief, allow us to pass along a quip from years past: When told the sky was falling, Chicken Little had but one reaction: Sell sky! And now, on with the show. Time for a cup of stimulation and a look at the to-do list. Hope your day goes well and you remain healthy.

In response to the novel coronavirus and drug shortages in general, two senators introduced a bill to funnel $100 million to increase U.S. production of medicines and active pharmaceutical ingredients, CNBC says. The legislation sponsored by Marsha Blackburn, R-Tenn., and Bob Menendez, D-N.J., would expand upon the Emerging Technology Program within the Food and Drug Administration to prioritize issues related to national security and critical drug shortages, as well as bring pharmaceutical manufacturing jobs to the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.